YK-209A

YK-209A · Suzhou Puhe Pharmaceutical Technology Co., LTD

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for YK-209A, covering 2023-03-17 to 2023-03-17. Get the full timeline:

Most recent: Clinical Trial Update: Assessing an Oral EGFR Inhibitor,YK-209A in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR [Phase 1, Phase 2]

See pricing